Original Article
The m6A readers *YTHDF1* and *YTHDF3* aberrations associated with metastasis and predict poor prognosis in breast cancer patients

Ramesh Anita[1*], Arumugam Paramasivam[3*], Jayaseelan Vijayashree Priyadharsini[3], Srinivasan Chitra[2]

*Departments of [1]Medical Oncology, [2]Pathology, Saveetha Medical College Hospital, Saveetha University, Chennai, India; [3]BRULAC-DRC, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, India. *Equal contributors and co-first authors.*

Abstract: N6-Methyladenosine (m6A) is the most common RNA modification in eukaryotic mRNAs and growing evidence suggests the crucial roles of m6A and its regulators in human tumorigenesis. Recent studies have shown that the m6A regulators promote tumorigenesis of various types of cancer. However, the underlying molecular mechanisms of m6A regulators in breast cancer remain largely unknown. We therefore assessed the genetic alterations, expression and prognostic role of m6A regulators in breast cancer using openly available data from The Cancer Genome Atlas (TCGA). Analysis of TCGA data revealed that m6A regulators including *KIAA1429*, *YTHDF1*, and *YTHDF3* were upregulated in breast cancer tissues, and the expression level significantly correlated with intrinsic subclasses and nodal metastasis. Importantly, we found for the first time that *YTHDF1* and *YTHDF3* were frequently amplified which contribute to the overexpression of *YTHDF1* and *YTHDF3* transcripts, thereby promoting breast cancer progression. Moreover, overexpression of *YTHDF1* and *YTHDF3* were associated with poor prognosis of breast cancer patients. Therefore, YTHDF1 and YTHDF3 serve a crucial role in the pathogenesis of breast cancer, which are potentially useful for prognosis stratification and therapeutic target for breast cancer.

Keywords: Breast cancer, m6A readers aberrations, prognostic signature, survival analysis

Introduction

Breast cancer is the second most common form of cancer afflicting women world-wide. According to the prediction by the American Cancer Society (ACS), breast cancer was responsible for about 41,760 cancer-related deaths in the United States in 2019 [1]. Despite remarkable advancements in the therapeutic modalities during recent years, the prognosis of breast cancer still remains poor. Therefore, further studies are required to determine the potential mechanism of oncogenesis and progression of breast cancer.

N6-methyladenosine (m6A) modification is one of the most common modification in eukaryotic mRNA that influences mRNA splicing, export, localization, translation, decay, and stability [2-5]. m6A RNA modification is reversible and catalyzed by a recently discovered multicomponent protein complex, including methyltransfer-ases (METTL3, METTL14, and KIAA1429), de-methylases (FTO and ALKBH5), and m6A binding proteins (YTHDF1-3, YTHDC1 and YTHDC2) [2-5]. A growing body of evidence suggested that m6A modification is involved in diverse biological processes including tissue development, embryonic stem cell self-renewal, and fate determination [2, 6]. Recent studies have shown that dysregulation of m6A modification is associated with cancer progression [2, 6].

YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) is a member of the YTH domain-containing proteins including YTHDF1-3, YTHDC1 and YTHDC2. Many studies recently, demonstrated that YTHDF1 function as "reader" of m6A-modified mRNAs and promotes translation in the cytosol [2, 5]. However, the relationship between YTHDF1 and different cancers are largely unknown, the more recent studies reported that YTHDF1 is closely related with initiation and progression of ovarian [2], HCC [7], and colon [8] cancers.

Therefore, in the present study, we first compared the transcriptional levels of m6A regulators in breast cancer and adjacent breast tissues using UALCAN database. In addition, the cBioPortal database was used to analyze the genetic alterations of *YTHDF1* and *YTHDF3,* and the correlation with transcriptional levels. Furthermore, the Kaplan-Meier plotter database was used to assess the prognostic effects of *YTHDF1* and *YTHDF3* mRNAs expression in patients with breast cancer. Overall, our results demonstrated that m6A regulators are the crucial participants in the malignant progression of breast cancer, which are potentially useful for prognosis stratification and therapeutic target for breast cancer.

Materials and methods

Gene expression and survival analysis

In the current study, UALCAN (http://ualcan.path.uab.edu/) [9] was applied to analyze the transcriptional levels of *YTHDF1* in primary breast cancer tissues and their association with intrinsic subclasses as well as to analyze the patient survival. In addition, we used the CCLE dataset (https://www.broadinstitute.org/ccle) [10] to analyze the *YTHDF1* transcript level in cancer cell lines. The prognostic value of *YTHDF1* in breast cancer patients were analyzed using Kaplan-Meier plotter (http://kmplot.com/analysis/).

Analysis of YTHDF1 alterations in breast cancer samples

The cBioPortal (www.cbioportal.org/) TCGA dataset is a user-friendly, interactive website resource and provides visualization, analysis, and download of large-scale cancer genomics datasets [11, 12]. In the present study, the c-BioPortal was utilized to analyze *YTHDF1* alterations in breast cancer samples.

Correlation analysis

Pearson correlation analysis was employed using the GEPIA dataset to reveal the association among different m6A RNA methylation regulators and their target genes.

In silico functional analysis

To evaluate the potential functional impact of missense mutations in *YTHDF1* gene, we utilised a variety of pathogenicity prediction pro-grams, including SIFT (http://sift.jcvi.org/), and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2//).

Results

YTHDF1 is up-regulated in the breast cancer tissue and cells

UALCAN database analysis revealed that *YTHDF1* mRNA expression of breast cancer significantly increased compared to the normal tissues (P=1.62e-12) (**Figure 1A**). In additions, *YTHDF1* mRNA level also was increased in breast cancer cells (**Figure 1B**). The mRNA of *YTHDF1* expression was significantly correlated with intrinsic subclasses of breast cancer (**Figure 1C**). The high expression of YTHDF1 was also crucial for breast cancer metastasis (**Figure 1D**).

Genetic alterations of YTHDF1 is associated with poor prognosis in breast cancer patients

We analysed the genetic alterations and expression levels of *YTHDF1* by using the cBioPortal TCGA dataset. Importantly, this gene displayed different mutations and expression patterns, among which *YTHDF1* gene was most frequently amplified (**Figure 2A**). Interestingly, we also observed that many *YTHDF1* mutations were novel (**Figure 2B**) may have strong functional consequences as predicted by *in silico* functional analysis (**Table 1**). Further, the copy number status of *YTHDF1* positively correlated with its mRNA expression in breast cancer patients (**Figure 2C**). Moreover, breast cancer patients with *YTHDF1* alterations have worse overall survival than breast cancer patients without *YTHDF1* alterations (P=3.923e-3), (**Figure 2D**). In addition, we found that the overexpression of *YTHDF1* correlated with the poor prognosis of breast cancer patients (P=0.013) (**Figure 2E**).

Genetic alterations of YTHDF3 is associated with poor prognosis in breast cancer patients

We also analysed the genetic alterations and expression levels of *YTHDF3* by using the cBioPortal TCGA dataset. Surprisingly, *YTHDF3* gene was most frequently amplified (14%) (**Figure 3A**). Further amplification of *YTHDF3* positively correlated with its mRNA expression in breast cancer patients (**Figure 3B**). Moreover, breast cancer patients with *YTHDF3* alterations

Figure 1. *YTHDF1* was overexpressed in breast cancer. Expression of *YTHDF1* significantly increased in breast cancer tissues compared with adjacent normal tissues (P=1.62e-12) (A) and breast cancer cells (B). The increased expression of *YTHDF1* correlated with intrinsic subclasses (C) and nodal metastasis (D).

have worse overall survival than breast cancer patients without *YTHDF3* alterations (P= 0.0165) (**Figure 3C**). In addition, we found that the overexpression of *YTHDF3* correlated with the poor prognosis of breast cancer patients (P=1.5e-11) (**Figure 3D**).

The m6A regulators target genes expression in breast cancer

UALCAN database and the Human Protein Atlas (https://www.proteinatlas.org/) analysis revealed that m6A regulators target mRNAs (CDK1, P<1e-12; MKI67, P=1.624e-12; VEGFA, P=1.624e-12) (**Figure 4A-C**) and their proteins (**Figure 4D-F**) were highly expressed in breast cancer tissues.

Correlation of m6A regulators in breast cancer

We analyzed the association among m6A regulators and their target genes using the GEPIA dataset. We found that the YTHDF1 positively corrected with YTHDF3 (R=0.34, P<0.05) (**Figure 5A**). Surprisingly, highly expressed KIAA1429 was positively corrected with CDK1

(R=0.067, P<0.05) (**Figure 5B**), and VEGFA (R=0.081, P<0.05) (**Figure 5C**).

Discussion

Emerging evidence support that dysregulation of m6A methylation is tightly associated with different cancers development. Recently, the results of multiple studies have shown that m6A regulators such as methyltransferases (METTL3, METTL14 and KIAA1429) and de-methylases (FTO and ALKBH5) play important roles in various cancers including lung cancer, breast cancer, acute myeloid leukemia, endometrial cancer, and glioma [13-17]. For example, overexpression of METTL3 and ALKBH5 were associated with poor survival time of breast cancer and glioma [18, 19].

Previous studies have reported that YTHDF1 was up-regulated in ovarian cancer [2], hepatocellular carcinoma [7], colorectal cancer [8], and lung cancer [13]. The up-regulated YTHDF1 correlated with the poor prognosis of ovarian cancer patients [2] and hepatocellular carcinoma [7]. In the present study, we found that

Figure 2. Correlation between the genetic alterations of *YTHDF1* and mRNA level in breast cancer tissues. Oncoprint in cBioPortal database exhibited the proportion and distribution of specimens with genetic alterations in *YTHDF1* (A). Schematic diagram of the YTHDF1 protein and the positions of mutations (red letters are novel mutations, that were not presented in gnomAD) (B). Copy gain (gain and amplification) of *YTHDF1* was associated with notably increased *YTHDF1* mRNA levels compared with the copy-neutral (diploid) and copy-loss (shallow deletion) cases (C). Survival analysis of breast cancer patients with and without *YTHDF1* gene alteration (D). The prognostic value of mRNA level of *YTHDF1* in breast cancer patients, analyzed by Kaplan-Meier plotter (P=0.013) (E).

Table 1. Summary of *YTHDF1* mutations

Mutation	SIFT	Polyphen-2	gnomAD
Q25H	Deleterious	Probably Damaging	No
S50*	NA	NA	No
F129L	Deleterious	Probably Damaging	1.732E-05
Q138E	Deleterious	Probably Damaging	No
S144N	Tolerated	Probably Damaging	No
P246H	Deleterious	Probably Damaging	No
P292L	Deleterious	Benign	No
I402M	Deleterious	Probably Damaging	No
E451K	Tolerated	Probably Damaging	7.074E-06

Abbreviations are follows: gnomAD, The Genome Aggregation database; NA, Not Applicable. *Truncating mutation.

YTHDF1 mRNA was up-regulated in breast cancer compared to the normal tissues and up-regulated *YTHDF1* correlated with the poor prognosis of breast cancer patients. Liu et al. recently reported that YTHDF1 was crucial for proliferation and metastasis of ovarian cancer using *in vitro* and *in vivo* studies [2]. Our results also showed that overexpression of *YTHDF1* significantly correlated with intrinsic subclasses and nodal metastasis of human breast cancer. Therefore, our findings suggest that high expressions of *YTHDF1* mRNA remarkably correlated with the poor prognosis of breast cancer patients, which might be identified as promising biomarkers to predict the survival of breast cancer patients.

Gene copy number alterations are an important cause that drives aberrant up-regulation of oncogenes in cancer [20, 21]. A recent study has shown that *YTHDF1* copy number gain was a major mechanism that contributes to high expression of YTHDF1 in human colorectal carcinoma [6]. In addition, Liu et al. more recently reported that *YTHDF1* gene was frequently amplified and increased in high-grade serous ovarian cancer [2], suggesting that YTHDF1 might be an important oncogene, which is selected during cancer evolution. Our finding is consistent with these reports that *YTHDF1* gene is frequently amplified and contributes to high expression of *YTHDF1* in human breast cancer. Surprisingly, *YTHDF3* is also frequently amplified (14%) and contributes to high expression of *YTHDF3* in human breast cancer. Importantly, we also found that breast cancer patients with *YTHDF1* and *YTHDF3* alterations have worse overall survival than breast cancer

patients without *YTHDF1* and *YTHDF3* alterations. Recent studies have demonstrated that YTHDF1 and YTHDF3 enhance the translation efficiency of m6A-modified mRNAs [22, 23]. Our findings demonstrated that *YTHDF1* and *YTHDF3* mRNAs were up-regulated in breast cancer, further *YTHDF1* was positively correlated with *YTHDF3*. Therefore, *YTHDF1* and *YTHDF3* amplifications, and their transcripts upregulation may promote the translation of oncogene targets in m6A-dependent manner that results in breast cancer development.

Multiple lines of evidence suggested that METTL3 and KIAA1429 were increased m6A level of cancer associated genes including CDK1, MKI67 and VEGFA [24-26]. Qian et al. recently reported that KIAA1429 played oncogenic role in breast cancer by regulating cyclin-dependent kinase 1 (CDK1) in m6A-independent manner [24]. Moreover, KIAA1429 also played a critical role in liver cancer development by regulating GATA3 in m6A-dependent manner [27]. In the present study, we found that KIAA1429, CDK1, MKI67, and VEGFA were highly expressed in breast cancer, further KIAA1429 was positively corrected with CDK1, and VEGFA. Therefore, we speculated that KIAA1429 plays an oncogenic role in breast cancer by regulating CDK1, MKI67, and VEGFA in m6A-dependent or independent manner.

The studies showed that YTHDF1 and YTHDF3 promotes protein synthesis by interacting with the translation machinery. Moreover, YTHDF1 regulated oncogenes translation by recruiting the initiation factor EIF3 [28] and elongation factor eEF-2 [29] via an m6A-dependent manner. Liu et al. recently reported that YTHDF1 facilitates the translation of EIF3C in an m6A-dependent manner and concomitantly enhanced the overall translational output, thereby promoting tumorigenesis and metastasis of ovarian cancer [2]. In addition, EIF3C was associated with malignant behavior of human breast cancer [30], we also observed that mRNA (UALCAN; P=9.765e-08) and protein (The Human Protein Atlas; https://www.proteinatlas.org/) of EIF3C was up-regulated in breast cancer. Therefore, our findings suggest that up-regulated YTHDF1 might enhance the translation of EIF3C in an m6A-dependent manner and promotes translation of oncogenic transcripts,

Figure 3. Correlation between the genetic alterations of *YTHDF3* and mRNA level in breast cancer tissues. Oncoprint in cBioPortal database exhibited *YTHDF3* amplification in breast cancer (A). Correlation between *YTHDF3* amplification and its mRNA level (B). Survival analysis of breast cancer patients with and without *YTHDF3* gene alteration (C). The prognostic value of mRNA level of *YTHDF3* in breast cancer patients, analyzed by Kaplan-Meier plotter (P=1.5e-11) (D).


Figure 4. The m6A regulators target genes expression in breast cancer. CDK1 (A), MKI67 (B) and VEGFA (C) mRNAs expression were analysed using UALCAN database. CDK1 (D), MKI67 (E) and VEGFA (F) proteins expression were analysed in breast cancer tissue using the Human Protein Atlas (https://www.proteinatlas.org/).

Figure 5. Correlation between the expression of YTHDF1 and YTHDF3 (A). Correlation between the expression of KIAA1429 and cancer associated genes CDK1 (B) and VEGFA (C).

thus facilitating oncogenesis and metastasis of breast cancer.

Most human cancers, including breast cancer contain many different types of mutations and majority of these are missense mutations which can dramatically increase the risk of developing certain cancers. BRCA1 and BRCA2 genes are the most frequently mutated genes that are associated with high breast cancer risk [31]. A recent study found that point mutations spread over the coding sequence of the BRCA1 and BRCA2 were attributed to an increased risk of breast cancer [31]. Interestingly, we found several novel point mutations in *YTHDF1* gene. The following lines of evidence support the pathogenic effects of these *YTHDF1* gene mutation including novel mutations: 1) conservation data suggests these mutations were highly conserved amino acid residues of YTHDF1 protein; 2) all novel mutations were absent in gnomAD; 3) *in silico* functional analyses predict the mutations to be pathogenic with high probability scores. Therefore, our findings suggest that point mutations in *YTHDF1* gene can vastly increase the risk of developing breast cancer.

In conclusion, the recent studies reported that *YTHDF1* copy number gain was most common genetic alterations and correlated with high expression of YTHDF1 which promoted development of cancers by regulating cancer-related gene expression. Importantly, we reported for the first time that *YTHDF1* and *YTHDF3* copy number gains were strikingly higher than other cancer which contributes to the overexpression of *YTHDF1* and *YTHDF3*, thereby promoting breast cancer progression. Therefore, *YTHDF1* and *YTHDF3* could be a promising prognostic

biomarker and potential therapeutic target for breast cancer.

Disclosure of conflict of interest

None.

Address correspondence to: Arumugam Paramasivam, BRULAC-DRC, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, Poonamallee High Road, Chennai, Tamilnadu 600077, India. Tel: 8790250246; E-mail: paramasivama.sdc@saveetha.com

References

[1]   Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.
[2]   Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, Xiao H, Li L, Rao S, Wang F, Yu J, Yu J, Zou D and Yi P. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res 2020; 48: 3816-3831.
[3]   Paramasivam A, Priyadharsini JV and Raghunandhakumar S. Implications of m6A modification in autoimmune disorders. Cell Mol Immunol 2019; 17: 550-551.
[4]   Paramasivam A and Vijayashree Priyadharsini J. Novel insights into m6A modification in circular RNA and implications for immunity. Cell Mol Immunol 2020; 17: 668-669.

[5] Paramasivam A, Vijayashree Priyadharsini J and Raghunandhakumar S. N6-adenosine methylation (m6A): a promising new molecular target in hypertension and cardiovascular diseases. Hypertens Res 2019: 43: 153-154.

[6] Bai Y, Yang C, Wu R, Huang L, Song S, Li W, Yan P, Lin C, Li D and Zhang Y. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol 2019; 9: 332.

[7] Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L and Sun X. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark 2018; 21: 859-868.

[8] Nishizawa Y, Konno M, Asai A, Koseki J, Kawamoto K, Miyoshi N, Takahashi H, Nishida N, Haraguchi N, Sakai D, Kudo T, Hata T, Matsuda C, Mizushima T, Satoh T, Doki Y, Mori M and Ishii H. Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer. Oncotarget 2018; 9: 7476-7486.

[9] Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017; 19: 649-58.

[10] Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R and Garraway LA. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.

[11] Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.

[12] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: l1.

[13] Shi Y, Fan S, Wu M, Zuo Z, Li X, Jiang L, Shen Q, Xu P, Zeng L, Zhou Y, Huang Y, Yang Z, Zhou J, Gao J, Zhou H, Xu S, Ji H, Shi P, Wu DD, Yang C and Chen Y. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun 2019; 10: 4892.

[14] Yi D, Wang R, Shi X, Xu L, Yilihamu Y and Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression. Oncol Rep 2020; 43: 1375-1386.

[15] Wu L, Wu D, Ning J, Liu W and Zhang D. Changes of N6-methyladenosine modulators promote breast cancer progression. BMC Cancer 2019: 19: 326.

[16] Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, Wu X and Wan G. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer 2019: 18: 46.

[17] Liu L, Liu X, Dong Z, Li J, Yu Y, Chen X, Ren F, Cui G and Sun R. N6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survival. J Cancer 2019: 10: 5447-5459.

[18] Wang H, Xu B and Shi J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2. Gene 2020; 722: 144076.

[19] Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bögler O, Majumder S, He C and Huang S. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 2017; 31: 591-606, e596.

[20] Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthäi A, Cuesta MA, Terhaar Sive Droste JS, Craanen M, Schröck E, Ylstra B and Meijer GA. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 2009; 58: 79-89.

[21] J. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, Hummon AB, Grade M, Ried T and Difilippantonio MJ. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 2009; 48: 1002-17.

[22] Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baidya P, Wang X, Bhattarai DP, Zhao YL, Sun BF and Yang YG. Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res 2017; 27: 444-447.

[23] Jin H, Ying X, Que B, Wang X, Chao Y, Zhang H, Yuan Z, Qi D, Lin S, Min W, Yang M and Ji W. N6-methyladenosine modification of ITGA6 mRNA promotes the development and pro-

gression of bladder cancer. EBioMedicine 2019; 47: 195-207.

[24] Qian JY, Gao J, Sun X, Cao MD, Shi L, Xia TS, Zhou WB, Wang S, Ding Q and Wei JF. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene 2019; 38: 6123-6141.

[25] Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bögler O, Majumder S, He C and Huang S. m 6 A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 2017; 31: 591-606, e6.

[26] Tian C, Huang Y, Li Q, Feng Z and Xu Q. Mettl3 regulates osteogenic differentiation and alternative splicing of vegfa in bone marrow mesenchymal stem cells. Int J Mol Sci 2019; 20: 551.

[27] Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y and Wu H. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer 2019; 18: 186.

[28] Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H and He C. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell 2015; 161: 1388-1399.

[29] Lin X, Chai G, Wu Y, Li J, Chen F, Liu J, Luo G, Tauler J, Du J, Lin S, He C and Wang H. RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. Nat Commun 2019; 10: 2065.

[30] Zhao W, Li X, Wang J, Wang C, Jia Y, Yuan S, Huang Y, Shi Y and Tong Z. Decreasing eukaryotic initiation factor 3C (EIF3C) suppresses proliferation and stimulates apoptosis in breast cancer cell lines through mammalian target of rapamycin (mTOR) pathway. Med Sci Monit 2017; 23: 4182-4191.

[31] Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR and Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol 2019; 12: 38.